Moderna (MRNA) reported a Q4 loss Friday of $2.91 per diluted share, swinging from a profit of $0.55 a year earlier.

Analysts polled by FactSet expected a loss of $2.83.

Revenue for the quarter ended Dec. 31 was $966 million compared with $2.81 billion a year earlier.

Analysts surveyed by FactSet expected $942.8 million.

The company reiterated its 2025 revenue guidance of $1.5 billion to $2.5 billion. Analysts polled by FactSet expect $2.36 billion.

Moderna shares fell more than 5% in premarket trading.